What Is the Success Rate of HoLEP Surgery?

HoLEP (holmium laser enucleation of the prostate) has one of the highest documented success rates among surgical treatments for benign prostatic hyperplasia (BPH), with patient satisfaction consistently around 92 to 95 percent and durable symptom relief persisting well beyond a decade in published follow-up data. The procedure uses a laser to shell out the obstructing prostate tissue from its capsule, and its outcomes rival or exceed those of both traditional surgery and newer alternatives. But “success” after a prostate procedure is not a single number; it depends on what you measure and how far out you look.

How Symptoms Improve After HoLEP

The most widely used yardstick for BPH surgery is the International Prostate Symptom Score (IPSS), a questionnaire that captures how much urinary bother a man experiences on a 0-to-35 scale. Before HoLEP, the typical patient scores somewhere in the high teens to low twenties, indicating moderate-to-severe symptoms. After surgery, that score drops sharply. In a large series of 774 patients with a median follow-up of about four years, the median IPSS fell from 19 before surgery to 3 afterward, and quality-of-life scores improved from 4 (mostly dissatisfied) down to 1 (mostly satisfied).¹ Those numbers are not quirks of a single center. A study tracking patients out to six years found that mean IPSS improved from about 17 to roughly 6, while peak urinary flow rate more than doubled, rising from around 6 to 16 milliliters per second.²

Flow rate and post-void residual volume (how much urine is left in the bladder after voiding) also show dramatic improvement. In one ten-year follow-up, patients averaged a flow rate above 23 milliliters per second and an IPSS below 4 a full decade after surgery, with quality-of-life scores near zero, the best possible rating.³ These results are not just statistically significant on paper; they translate into men going from waking up several times a night to urinate to sleeping through most of the night, and from straining at the toilet to voiding comfortably.

How Long the Results Last

A concern with any prostate procedure is whether tissue regrows and symptoms return. HoLEP has an edge here because it removes almost all of the obstructing adenoma rather than shaving or vaporizing layers off the surface. That near-complete removal translates to very low reoperation rates. In the ten-year follow-up mentioned above, only about 0.7 percent of patients required a second procedure for residual tissue.³ That is remarkably low when compared to the roughly 5 to 15 percent retreatment rates reported for some other BPH procedures over similar timeframes.

The benefits do gradually soften. A five-year single-center study found that while improvements remained substantial at year five, peak flow rate had declined by about 23 percent from its immediate postoperative peak, and IPSS had risen modestly.⁴ This is not the same as a return to pre-surgery misery. Think of it more as a slow relaxation from “excellent” toward “very good.” The vast majority of men still report far better urinary function years later than they had before surgery.

Patient Satisfaction Numbers

Objective measures like flow rates and symptom scores can feel abstract. What actually matters to most men is whether they are glad they had the surgery. In a prospective study specifically designed to capture this, about 92 percent of patients said they were satisfied with the outcome, and 94 percent said they would choose to have the procedure again if they had to make the decision over.⁵ Fewer than 4 percent described themselves as dissatisfied, and essentially no one chose “very dissatisfied.” A separate quality-of-life assessment found satisfaction with the hospital stay and treatment at around 95 percent, with positive quality-of-life ratings climbing from about 62 percent right after surgery to 86 percent at three months as recovery progressed.⁵

How HoLEP Compares to TURP

Transurethral resection of the prostate (TURP) has been the reference standard for decades, so the natural question is how HoLEP stacks up. The short answer: equivalent symptom improvement, but HoLEP wins on recovery speed. In head-to-head comparisons, both procedures produced similar improvements in IPSS, with no statistically significant difference.⁶ Where HoLEP consistently comes out ahead is in catheterization time (roughly one day versus two to three days) and hospital stay (one day versus three).⁶ Another comparative study confirmed shorter catheter and irrigation times for HoLEP, with similar functional results maintained at nine months.⁷

For very large prostates, HoLEP also outperforms robotic-assisted simple prostatectomy (RASP). A meta-analysis found equivalent functional outcomes between the two, but HoLEP shaved roughly 50 minutes off operative time, reduced hospitalization by about a day and a half, shortened catheterization by nearly four days, and cut the risk of blood transfusion by 75 percent. Patients who had RASP were nearly twice as likely to have moderate complications and over three times as likely to develop serious ones.⁸

Prostate Size Does Not Limit the Procedure

One of HoLEP’s distinguishing features is that it works regardless of prostate size. Many BPH procedures become impractical or less effective once the gland exceeds about 80 to 100 grams. HoLEP has been studied in prostates over 100, 175, and even 200 cubic centimeters. A randomized trial comparing HoLEP to open prostatectomy in prostates over 100 grams found equally good urinary improvements at five years, with similarly low reoperation rates.⁹ A series focusing specifically on glands over 175 grams confirmed satisfactory outcomes with low complication rates, calling HoLEP the only endoscopic technique that can remove tissue volumes comparable to open surgery.¹⁰ Even at 200 cubic centimeters and above, researchers found the procedure feasible with minimal additional risk.¹¹

Complications and What to Expect During Recovery

No surgery is complication-free, and knowing the realistic risks is part of understanding “success.” The most talked-about side effect is temporary urinary incontinence, especially stress-type leakage. Studies report transient incontinence in roughly 9 to 17 percent of patients in the early postoperative period, but the large majority resolve within weeks.¹²¹³ In one single-surgeon series of nearly 600 patients, about 9 percent had transient stress incontinence, and almost 90 percent of those cases resolved within six weeks. Long-term stress incontinence affected only 1.5 percent.¹² Ten-year data put persistent stress incontinence at about 0.5 percent and urge incontinence at about 1 percent.³

An interesting anatomical factor plays into incontinence recovery. Men with a longer membranous urethra (the segment of the urethra that runs through the external sphincter) tend to regain continence faster. One study found that men with a membranous urethra of 14 millimeters or longer had an 80 percent continence rate at just one month, while those with shorter ones were continent only 30 percent of the time at that point. By six months, both groups converged at around 97 percent.¹⁴ If your surgeon mentions membranous urethral length on imaging beforehand, this is why it matters.

Urethral stricture and bladder neck contracture are rarer but can require follow-up intervention. A seven-year experience at one center found urethral stricture in about 2 percent of patients and bladder neck contracture in about 1.4 percent.¹⁵ A larger long-term study reported urethral strictures in 5 percent and bladder neck strictures in 2 percent, with most developing within two years and most being short-segment and treatable.¹⁶ Longer operative time was a consistent risk factor across studies.¹⁷

Impact on Sexual Function

Erectile function generally stays intact after HoLEP. Two studies using validated sexual health questionnaires found no significant decline in erectile function scores after the procedure.¹⁸¹⁹ This is meaningful because many men worry that prostate surgery will cause impotence, and HoLEP data consistently shows it does not.

Ejaculation is a different story. Like most BPH surgeries, HoLEP disrupts the bladder neck in a way that causes retrograde ejaculation, where semen goes backward into the bladder instead of forward. One study found retrograde ejaculation in about 63 percent of patients.¹⁸ Ejaculatory function scores, which measure things like volume and force, did decline after surgery.¹⁹ The one reassuring detail is that bother scores related to ejaculatory changes did not significantly worsen. In other words, while the physical function changed, most men were not particularly distressed by it. Men for whom antegrade ejaculation is a priority should discuss this trade-off carefully before surgery.

HoLEP for Urinary Retention

Men who are completely unable to urinate and rely on a catheter represent a particularly challenging group. HoLEP is effective even in these cases. In one study, nearly 99 percent of men with acute urinary retention and the same proportion with chronic non-neurogenic retention were catheter-free three months after HoLEP.²⁰ A separate retrospective study found a 12-month catheter-free rate of about 96 percent in retention patients, comparable to the 99 percent rate in men who had surgery for lower urinary tract symptoms alone.²¹

Even men with weak bladder muscle contractions, a condition called detrusor underactivity, can benefit. A long-term study found that about 89 percent of men with underactive detrusors and 63 percent of men with fully acontractile bladders were catheter-free after HoLEP, with follow-up extending past three years.²² The thinking is that in many cases, the bladder weakness is a consequence of the obstruction, and once the blockage is removed, the muscle gradually recovers.²³

Blood Thinners and High-Risk Patients

Because the holmium laser cauterizes tissue as it cuts, HoLEP has a natural hemostatic advantage. This raises the question of whether men on blood-thinning medications can safely undergo it. The evidence is generally reassuring, with an important caveat about the type of blood thinner.

One large study found that while overall complication rates were higher in patients on anticoagulant therapy, the rate of major complications (the serious ones requiring intervention) was not significantly elevated. The independent predictors of complications were age, health status, and incidental prostate cancer, not the blood-thinning medication itself.²⁴ A separate analysis found HoLEP to be safe whether antiplatelet or anticoagulation therapy was held or continued through surgery.²⁵

The caveat: full-dose anticoagulation therapy (drugs like warfarin at therapeutic levels) did carry meaningfully higher bleeding-related readmission rates compared to antiplatelet therapy (about 16 percent versus 2 percent in one study). Anticoagulation was the only independent predictor of hemorrhagic complications in that analysis.²⁶ If you take blood thinners, this is a conversation to have with both your urologist and your cardiologist about balancing bleeding risk against clotting risk.

The Learning Curve Factor

HoLEP is technically demanding. Unlike TURP, which most urologists learn during residency, HoLEP requires the surgeon to develop a feel for separating the adenoma from the capsule in three-dimensional space. The learning curve affects your outcome more than most patients realize.

A review of over a thousand cases found that experience with at least 20 cases significantly improved surgical efficiency and incontinence rates.²⁷ But the curve does not really plateau for a long time. A recent analysis found that complication rates, including bleeding requiring treatment and urinary retention, continued to drop significantly up to 350 cases, with operative proficiency still improving even beyond that mark.²⁸ A 500-case single-surgeon series using the en-bloc technique showed enucleation efficiency (grams removed per minute) steadily climbing across the entire series, and operative times falling from 67 minutes early on to 43 minutes later.²⁹

The practical takeaway: when choosing a HoLEP surgeon, volume matters. A surgeon who has performed hundreds of these procedures will generally be faster, cause less bleeding, and produce lower incontinence rates than one just starting out. It is entirely reasonable to ask how many HoLEPs your surgeon has done.

Same-Day Discharge and Outpatient HoLEP

Traditionally, HoLEP meant at least one overnight stay. That is changing. Several centers now perform HoLEP as a same-day surgery with catheter removal before the patient goes home. A systematic review found same-day catheter removal success rates in the range of 85 to 90 percent among selected patients, with almost no serious complications reported.³⁰ A study comparing same-day discharge patients to those who stayed overnight found no difference in complication rates, readmission rates, or one-year functional outcomes.³¹

Same-day discharge tends to work best for men with smaller prostates, shorter operative times, and no history of urinary retention. A structured outpatient protocol, including early morning scheduling and avoiding opioid-based anesthesia, helps make it feasible.³² Using the Moses laser technology, which modifies how laser energy is delivered, has been associated with more same-day discharges and roughly $750 to $840 in cost savings per case compared to standard HoLEP setups.³³

Cost-Effectiveness Over Time

HoLEP is not the cheapest option upfront. A cost-effectiveness analysis estimated the five-year per-patient cost of HoLEP at about $6,500, compared to roughly $6,700 for TURP and around $3,300 for watchful waiting with medical therapy. But HoLEP produced the highest quality-adjusted life years among all surgical options, making it the most cost-effective surgical choice when balancing cost against benefit. If follow-up time extended further, HoLEP’s advantage grew more pronounced, because its low reoperation rate means fewer downstream costs.³⁴ For large prostates where open or robotic simple prostatectomy would be the alternative, HoLEP was both less expensive and more effective.

The Hidden Diagnostic Bonus

Because HoLEP removes the entire adenoma as intact tissue (rather than vaporizing it), the specimen goes to pathology for examination. This occasionally turns up prostate cancer that nobody suspected. Two recent studies both found incidental prostate cancer in about 7 to 8 percent of HoLEP specimens.³⁵³⁶ Of those, roughly a third had clinically significant cancer requiring further evaluation or treatment. This is not a reason to have HoLEP, but it is a meaningful fringe benefit: unlike vaporization techniques that destroy all the tissue, HoLEP gives pathologists something to examine.

What Happens to PSA After Surgery

PSA (prostate-specific antigen) levels often drive the anxiety that leads men to a urologist in the first place. After HoLEP, PSA drops dramatically because most of the gland tissue producing it has been removed. One large study of nearly 1,300 patients found an average PSA reduction of about 67 percent at six months, with men who started with elevated PSA seeing a nearly 80 percent drop. At six months, over 95 percent of men who had elevated PSA before surgery had levels that normalized.³⁷ A separate analysis found that PSA dropped from an average of about 6.3 to 0.6 at three months and remained stable at that lower level through one year of follow-up.³⁸

This PSA reduction itself is durable evidence that the gland tissue has been effectively removed and is not growing back. Researchers have also noted that if PSA starts climbing again during follow-up, it can serve as an early signal to investigate for prostate cancer, since the normal benign tissue that would explain a rising PSA has largely been taken away.³⁹ In a sense, HoLEP simplifies future PSA monitoring by establishing a clear new baseline.